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Abstract: Antimicrobial photodynamic therapy (aPDT) has emerged in the clinical field as 
a potential alternative to antibiotics to treat microbial infections. No cases of microbial 
viability recovery or any resistance mechanisms against it are yet known. 5,10,15-tris(1-
Methylpyridinium-4-yl)-20-(pentafluorophenyl)-porphyrin triiodide (Tri-Py
+-Me-PF) was 
used as photosensitizer. Vibrio fischeri and recombinant Escherichia coli were the studied 
bacteria. To determine the bacterial recovery after treatment, Tri-Py
+-Me-PF (5.0 µM) was 
added to bacterial suspensions and the samples were irradiated with white light (40 W m
-2) 
for 270 minutes. Then, the samples were protected from light, aliquots collected at 
different intervals and the bioluminescence measured. To assess the development of 
resistance after treatment, bacterial suspensions were exposed to white light (25 minutes), 
in presence of 5.0 μM of Tri-Py
+-Me-PF (99.99% of inactivation) and plated. After the first 
irradiation period, surviving colonies were collected from the plate and resuspended in 
PBS. Then, an identical protocol was used and repeated ten times for each bacterium. The 
results suggest that aPDT using Tri-Py
+-Me-PF represents a promising approach to 
efficiently destroy bacteria since after a single treatment these microorganisms do not 
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recover their viability and after ten generations of partially photosensitized cells neither of 
the bacteria develop resistance to the photodynamic process. 
Keywords: cationic porphyrin; antimicrobial photodynamic therapy; bacterial resistance; 
bacterial viability; bioluminescence 
 
1. Introduction 
The use of antibiotics to destroy selectively microorganisms (MO) represents one of the most 
revolutionary progresses made in scientific medicine, resulting in the treatment and sometimes 
complete eradication of earlier incurable diseases  [1,2]. It might have been supposed that at the 
beginning of the twenty first century, microbiologically-based diseases would have been reduced to a 
level that no longer had a serious impact on human health. However, bacteria have developed 
resistance mechanisms against antimicrobial drugs which were previously highly effective. Besides, 
bacteria replicate very rapidly and a mutation that helps a MO to survive in the presence of an 
antibiotic will quickly become predominant in the microbial population [1,3]. Due to resistance to all 
β-lactam antibiotics, the glycopeptide antibiotic vancomycin has remained as last line of defense 
against Gram-positive bacteria. However, methicillin-resistant Staphylococcus aureus and 
vancomycin-resistant enterococci are species that are causing much concern at present [4] and there is 
an urgent need for the development of novel, convenient, non-resistant and inexpensive measures for 
fighting microbial diseases [1,5,6]. 
Antimicrobial photodynamic therapy (aPDT) represents a potential alternative methodology to 
inactivate microbial cells [7–9] and has already shown to be effective in vitro against bacteria, fungi, 
viruses and protozoa [5,10–17]. The aPDT approach is based on the photodynamic therapy concept 
that comprises the action of three components: a photosensitizing agent (PS), a light source of an 
appropriate wavelength (artificial light or sunlight) and oxygen  [1,5,18–20]. Two oxidative 
mechanisms of photoinactivation (PI) are considered to be implicated in the inactivation of the target 
cells. The type I pathway involves electron/hydrogen atoms-transfer reactions from the PS triplet state 
with the participation of a substrate to produce radical ions while the type II pathway involves energy 
transfer from that triplet state to molecular oxygen to produce singlet oxygen (
1O2) [3,5,21–23]. Both 
processes lead to highly toxic reactive oxygen species (ROS) such as 
1O2 and free radicals, able to 
irreversibly alter vital components of cells resulting in oxidative lethal damage  [24,25]. The main 
advantages of aPDT are the non-target specificity, the few side effects, the prevention of the regrowth 
of the MO after treatment and the lack of development of resistance mechanisms due to the mode of 
action and type of biochemical targets (multi-target process) [9,20]. 
The photodynamic activity produces damages mainly in the cytoplasmatic membrane and in 
DNA [3]. The damages to the cytoplasmatic membrane can involve leakage of cellular contents or 
inactivation of membrane transport systems and enzymes [26,27]. Some damages produced in the 
DNA chain can be repaired by the action of DNA repairing systems [28]. However, it was shown that 
although DNA damage occurs it cannot be the main cause of bacterial cell photodynamic Mar. Drugs 2010, 8                                                 
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inactivation [3,29], since Deinococcus radiodurans, which is known to have a very efficient DNA 
repair mechanism, is easily killed by aPDT [30]. 
Although various studies have investigated the possible recovery of bacterial infections in animal 
models (in vivo) [31–33], there are no published results from studies that tested the possible viability 
recovery, in vitro, after aPDT treatment. Moreover, despite the fact various authors have stated that 
resistance to aPDT is unlikely to occur due to the non-specific killing mechanism (ROS cause damage 
on diverse bacterial structures) [34–41], only a few studies were conducted in order to determine if 
bacterial resistance occurs after several consecutive aPDT treatments. Cell wall structures and 
membranes are the main targets of photodynamic therapy drugs, and for this reason the drugs do not 
necessarily need to enter the cell. Specific and proper adhesion to these structures is usually considered 
sufficient for light-activated destruction of the target cell. Thus target cells have no chance to develop 
resistance by stopping uptake, increasing metabolic detoxification or increasing export of the drug [9].  
The research concerning aPDT is more focused in the identification of new PS that kill rapidly and 
efficiently the MO and in the disclosure of their inactivation mechanisms. However, and regarding the 
emergence of bacterial resistance to antibiotics, it is important to control the PI process in terms of 
resistance development. Lauro et al. [42] investigated the selection of resistant bacterial strains in 
Peptostreptococcus micros and Actinobacillus actinomycetemcomitans  after repeated photo-
sensitization of surviving cells with the porphycene-polylysine conjugates 2,7,12,17-tetrakis(2-
methoxyethyl)-9-glutaramidoporphycene and 2,7,12,17-tetrakis(2-methoxyethyl)-9-p-carboxybenzyl-
oxyporphycene. The results obtained by this group showed that the photosensitization of P. micros and 
A. actinomycetemcomitans by both PS induced no appreciable development of resistance in partially 
inactivated bacterial cells. The efficiency of photokilling underwent no change in ten subsequent 
irradiation sessions, even though cells which were damaged in a previous treatment were cultivated 
and re-exposed to porphycene and light [42]. Pedigo et al. [43] studied the possible development of 
bacterial resistance to aPDT after several treatments in antibiotic sensitive (MSSA) and resistant 
strains (MRSA) of S. aureus and antibiotic sensitive Escherichia coli. Bacteria were exposed to 
repetitive aPDT treatments using methylene blue as PS. The parameters were adjusted such that 
photoinactivation were lowest than 100% so that surviving colonies could be employed for subsequent 
exposures. No significant difference in E. coli cell death was observed through eleven repeated aPDT 
treatments. Similar results were observed using MSSA and MRSA, for which the killing rate did not 
significantly differ from over twenty five repeated exposures [43]. Jori et al. [44] determined that up to 
five consecutive generations of extensively photoinactivated MRSA (ca. 90%) show essentially 
identical degrees of sensitivity to phthalocyanine photosensitization. Although the known studies 
indicate that bacterial resistance to aPDT is unlikely, it is an important parameter to be evaluated when 
a new PS is considered for aPDT. 
The bacterial bioluminescence method is considered to be a rapid, sensitive and cost-effective 
choice  [12,45–47] to monitor the possible development of resistance after consecutive aPDT 
treatments, once that the photodynamic activity can be measured directly, continuously and in a non-
destructively high-throughput screening or continuous-culture way [48]. A strong correlation between 
bioluminescence and viable counts was demonstrated in experimental systems [12,49,50], where the 
light output reflects the actual cells metabolic rate. Mar. Drugs 2010, 8                                                 
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The aim of this study is to determine if in the presence of 5,10,15-tris(1-methylpyridinium-4-yl)-20-
(pentafluorophenyl)porphyrin triiodide (Tri-Py
+-Me-PF; Figure 1) the bacterial cells can recover their 
activity after photodynamic treatment and develop resistance to aPDT after repeated photodynamic 
treatments. The Tri-Py
+-Me-PF is a tricationic porphyrin recently described by our group. We have 
shown that it is a promising PS for the inactivation of several types of MO [10–12,16,17,51]. 
To achieve the goals indicated above, the bacterial bioluminescent method was selected to monitor 
the bacterial activity of two bioluminescent Gram-negative bacteria: the non-transformed Vibrio 
fischeri and the recombinant Escherichia coli.  
Figure 1. The structure of 5,10,15-tris(1-methylpyridinium-4-yl)-20-(pentafluorophenyl)-
porphyrin triiodide. 
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2. Results and Discussion 
2.1. Results 
The bacterial strains used in this work were a recombinant bioluminescent strain of E. coli 
described in a previous work [12] and the bioluminescent marine bacterium Vibrio fischeri ATCC 
49387. Knowing that the light emission in these bacteria is directly proportional to their metabolic 
activity  [12], we used their bioluminescence ability to evaluate their recovery after photodynamic 
treatment. The possible development of bacterial resistance after several aPDT treatments with   
Tri-Py
+-Me-PF as PS was also evaluated using the bioluminescence method. 
2.1.1. Bioluminescence versus CFU of an overnight culture 
To evaluate the correlation between the colony-forming units (CFU) and the bioluminescence signal 
of  V. fischeri and E. coli, the assays were carried out in dark conditions, with and without   
Tri-Py
+-Me-PF porphyrin. A linear correlation between viable counts and the bioluminescence signal 
of overnight cultures of both bioluminescent strains was observed (Figure 2). These correlations are 
similar in the presence and in the absence of Tri-Py
+-Me-PF and the bioluminescence results reflect the 
viable bacterial abundance. 
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Figure 2. (a) Relationship between the bioluminescence signal and viable counts of 
overnight cultures of bioluminescent marine bacterium Vibrio fischeri (10
9 CFU mL
-1) 
serially diluted in PBS with 3% of NaCl. (b) Relationship between the bioluminescence 
signal and viable counts of overnight cultures of recombinant bioluminescent Escherichia 
coli (10
8 CFU mL
-1) serially diluted in PBS. Viable counts are expressed in CFU mL
-1 
and bioluminescence in relative light units (RLU). The values are expressed as the means 
of two independent experiments; error bars indicate the standard deviation. (---- bacterial 
suspension in the absence of PS, ―― bacterial suspension with 5.0 µM of Tri-Py
+-Me-
PF incubated 4h in the dark). 
2.1.2. aPDT recovery study 
The ability of V. fischeri and E. coli cells to recover metabolic activity after a photodynamic 
treatment with 5.0 µM of Tri-Py
+-Me-PF is represented in Figure 3 and Figure 4, respectively. After 
270 minutes of irradiation, the limits of detection for both bacteria were reached and a reduction of  
5.1 log units on the bioluminescence signal of V. fischeri and 6.4 log units for bioluminescent E. coli 
was observed. Moreover, light and dark controls showed that the viability of these bacteria was neither 
affected by irradiation itself nor by the Tri-Py
+-Me-PF in dark conditions (Figures 3A and 4A). This 
confirms that the reductions obtained on cell viability after irradiation of the treated samples are due to 
the photosensitizing effect of the porphyrin. 
After one week of incubation in culture medium in dark conditions and in growth medium   
(Figures 3B and 4B), it was observed that the bioluminescence signal of photodynamic treated samples 
of  V. fischeri and E. coli was unchanged during all period of incubation (log bioluminescence   
≈-1.5 RLU for both V. fischeri and E. coli cells). No colonies were observed in the non-diluted (10
0) 
treated aliquot after plating in TSA medium with or without addition of NaCl, which is consistent with 
the bioluminescence results. It was also observed a decrease on the bioluminescence signal of light and 
dark controls of these bacteria. 
(a)  (b) 
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Figure 3. (a) Bioluminescence monitoring of V. fischeri treated with Tri-Py
+-Me-PF at  
5.0 µM after 15, 30, 45, 60, 90, 180 and 270 minutes of irradiation with white light   
(40 W m
-2). (b) Bioluminescence signal of V. fischeri 24, 48, 72 and 168 hours after the 
photodynamic treatment. The values are expressed as the means of two independent 
experiments; error bars indicate the standard deviation. (-- dark control, -- light control, 
-- Tri-Py
+-Me-PF + light). 
 (a) 
 
(b) 
 
Figure 4. (a). Bioluminescence monitoring of E. coli treated with Tri-Py
+-Me-PF at   
5.0 µM after 15, 30, 45, 60, 90, 180 and 270 minutes of irradiation with white light   
(40 W m
-2).  (b)  Bioluminescence signal of E. coli 24, 48, 72 and 168 hours after the 
photodynamic treatment. The values are expressed as the means of two independent 
experiments; error bars indicate the standard deviation. (-- dark control, -- light control, 
-- Tri-Py
+-Me-PF + light). 
(a)  (b) 
2.1.3. aPDT resistance study 
The effect of repeated treatments of bacterial suspensions of V. fischeri or E. coli with 5.0 μM of 
Tri-Py
+-Me-PF to white light (40 W m
-2) for 25 minutes are represented in Figure 5. The PI efficiency Mar. Drugs 2010, 8                                                 
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by Tri-Py
+-Me-PF against both strains was not affected during the ten generations of photosensitized 
cells. After 25 min of irradiation at 40 W m
-2 the Tri-Py
+-Me-PF was able to destroy 99.99% of V. 
fischeri and E. coli cells. 
Figure 5. Photodynamic inactivation efficiency of ten consecutive generations of   
(a) V. fischeri and (b) E. coli by 5.0 µM of Tri-Py
+-Me-PF after 25 min of irradiation with 
white light (40 W m
-2), using the bacterial bioluminescence method. N0 and N represent, 
respectively, bioluminescence signal before and after the irradiation [42]. The values are 
expressed as the means of three independent experiments; error bars indicate the standard 
deviation. 
(a)  (b) 
2.2. Discussion 
Microorganisms have adopted a variety of mechanisms to increase their resistance to antimicrobial 
drugs. These mechanisms comprise a thickening of their outer wall, encoding of new proteins which 
prevent the penetration of drugs, and onset of mutants deficient in porin channels allowing the influx 
of externally added chemicals [52–54]. The emergence of antibiotic resistance by pathogenic MO has 
led to the search of efficient alternative methods for which mechanisms of resistance must not 
occur [3,55]. The aPDT represents a potential approach to inactivate pathogenic MO [7,8] and has 
already shown to be efficient against bacteria, yeasts, viruses, and protozoa [5,10–16,18]. The main 
advantages of aPDT are the MO non-target specificity, the few side effects, the prevention of the 
regrowth of the MO after treatment and the potential lack of development of resistance mechanisms 
due to a multi-target process [9,20].  
The results of this study shown that both bacteria when treated with the tricationic porphyrin   
Tri-Py
+-Me-PF and irradiated with white light (40 W m
-2) for 270 minutes are unable to recover 
metabolic activity. When samples were maintained for one week in dark conditions and under medium 
growth, after the photodynamic treatments, the bioluminescence signal remains the same for both V. 
fischeri and E. coli cells during all period of incubation (≈-1.5 log RLU). The bioluminescence signal 
reduction observed in dark and light controls can be due to the lack of nutrients and/or the 
accumulation of toxic products from bacteria metabolism. It was also clear that the results obtained in 
this study corroborate the literature  [42–44] relative to the absence of resistance mechanisms after the Mar. Drugs 2010, 8                                                 
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photodynamic process. In fact, no significant reduction in the efficiency of photosensitization of V. 
fischeri and E. coli was observed after ten consecutive photosensitization sessions of   
25 minutes with 5.0 µM of Tri-Py
+-Me-PF. If bacterial resistance would occur, important reductions 
on the bacterial photoinactivation efficiency would be detected between experiments (and the 
irradiation time required to reach 99.99% of photosensitized cells should increase). Various authors 
affirmed that cultures on stationary phase show a certain degree of resistance to the PS  [34,56]. 
However, others refer that bacteria susceptibility to PS is independent from the growth phase [57,58]. 
In this study, the cultures were used at the same growth phase for all assays (stationary growth phase). 
As the bacterial colonies have been aseptically removed from the plate and resuspended in PBS, the 
cellular density obtained after the colony resuspension could be different. To avoid differences in the 
PI efficiency due to different bacterial densities, this parameter was controlled in all the experiments 
by measuring the optical density of the bacteria suspension before each assay. 
3. Experimental Section 
3.1. Photosensitizer 
The tricationic porphyrin used in this work [5,10,15-tris(1-methylpyridinium-4-yl)-20-(penta-
fluorophenyl)porphyrin  triiodide, Tri-Py
+-Me-PF] was prepared in two steps according to the 
literature [59]. A 500 µM stock solution of Tri-Py
+-Me-PF porphyrin in DMSO was prepared and 
maintained at 4 °C. 
3.2. Bacterial strains and growth conditions  
The bacterial strains used in this work were a recombinant bioluminescent strain of E. coli prepared 
in a previous work [12] and the bioluminescent marine bacterium Vibrio fischeri ATCC 49387. Both 
E. coli and V. fischeri were stored at -80 °C in 10% glycerol. Before each assay, an aliquot of V. 
fischeri was aseptically plated on tryptic soy agar (TSA, Merck) complemented with 3% of NaCl 
(because of the osmotic pressure required to natural light emission to occur) and grown for one day at 
25 °C. Next, one colony was aseptically inoculated on 30 mL Luria-Bertani broth with saline medium 
(LBS; 10 g of tryptone, 5 g of yeast extract and 30 g NaCl per liter; pH 7.5) [60] and grown for one 
day at 25 °C under stirring (100 rpm). An aliquot of this culture (240 µL) was subcultured in 30 mL of 
LBS and grown overnight at 25 °C under stirring (100 rpm). The same procedure was carried out with 
an E. coli strain containing two plasmids that confer resistance to two antibiotics: ampicilin (Amp) and 
chloramphenicol (Cm). For that reason, E. coli was aseptically plated on TSA with 100 mg mL
-1 of 
Amp and 25 mg mL
-1 of Cm and grown for one day at 25 °C. Next, one colony was aseptically 
inoculated on tryptic soy broth (TSB, Merck) with both antibiotics and grown for one day at 25 °C 
under stirring (100 rpm). Then, an aliquot of this culture was subcultured in 30 mL of TSB with Amp 
and Cm and grown overnight at 25 °C under stirring (100 rpm). Mar. Drugs 2010, 8                                                 
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3.3. Irradiation conditions 
The studies were carried out by exposing the samples to white light (PAR radiation, 13 lamps 
OSRAM 21 of 18 W each one, 380–700 nm) with a fluence rate of 40 W m
-2 (measured with a 
radiometer LI-COR Model LI-250). As V. fischeri emits light at temperatures below 30 °C [61], the 
samples were placed on a tray with water in order to maintain the samples at a constant   
temperature (25–28 °C). 
3.4. Bioluminescence versus CFU 
To evaluate the correlation between the CFU and the bioluminescence signal of V. fischeri, two 
assays were carried out in dark conditions, with and without Tri-Py
+-Me-PF porphyrin. Two 
suspensions were prepared from an overnight culture of V. fischeri, diluting the culture (1:10) in fresh 
phosphate buffered saline with 3% of NaCl (PBS with 3% of NaCl: 30 g NaCl, 0.2 g KCl, 1.44 g 
Na2HPO4 and 0.24 g KH2PO4 per liter; pH 7.4) to a final concentration of 10
7 CFU mL
-1. In one of 
these bacterial suspensions, an appropriate volume of porphyrin was added to achieve a final 
concentration of 5.0 µM, followed by a dark incubation for 4 h at 25–28 °C under stirring. Next, both 
suspensions were serially diluted (10
-1–10
-7) in PBS with 3% of NaCl. The non-diluted (10
0) and the 
diluted aliquots were plated in TSA with 3% of NaCl (100 µL) and, simultaneously, were read on a 
luminometer (500 µL) (TD-20/20 Luminometer, Turner Designs, Inc., USA) to determine the 
bioluminescence signal. The correlation between the CFU and the bioluminescence signal of E. coli 
was evaluated following the procedure described above for V. fischeri. However, the cultures and 
suspensions were diluted in PBS (PBS; 8 g NaCl, 0.2 g KCl, 1.44 g Na2HPO4 and 0.24 g KH2PO4 per 
liter; pH 7.4) and pour plated in TSA without NaCl. Both experiments were done in duplicate and the 
results were averaged. 
3.5. aPDT recovery study 
A photodynamic inactivation assay was conducted in order to determine if bacterial cells can 
recover their metabolism after an effective treatment. For this purpose, cultures of V. fischeri and E. 
coli were grown overnight and diluted tenfold in PBS (supplemented with 3% NaCl in the case of V. 
fischeri) to a final concentration of 10
7 CFU mL
-1. These bacterial suspensions were equally 
distributed in 600 mL sterilized and acid-washed beakers. Afterwards, the appropriate volume of   
Tri-Py
+-Me-PF solution was added to achieve a final concentration of 5.0 µM (total volume in the 
beakers was 15 mL). The samples were protected from light with aluminum foil and incubated for  
10 min at 25–28 °C, under stirring (100 rpm), to promote the porphyrin binding to bacterial cells. 
Then, the mixtures were exposed to white light with a fluence rate of 40 W m
-2 for 270 minutes 
(corresponding to a light fluence of 64.8 J cm
-2) under 100 rpm (25–28 °C). Aliquots of treated and 
control samples were collected at time 0 and after 15, 30, 45, 60, 90, 180 and 270 min of light 
exposure and the bioluminescence signal was measured in the luminometer. After 270 min of 
irradiation, when all bacteria were inactivated to the detection limit of the method, the samples were 
protected from light with aluminum foil and maintained under stirring at 25–28 °C. Aliquots of 
samples irradiated for 270 min and control samples were collected after 24, 48, 72 and 168 hours  Mar. Drugs 2010, 8                                                 
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post-irradiation and the bioluminescence signal was measured in the luminometer. Light and dark 
controls were included in all experiments. In the light control no Tri-Py
+-Me-PF was added, but the 
beaker was exposed to the same irradiation protocol. In the dark control, the Tri-Py
+-Me-PF was added 
to achieve a final concentration of 5.0 µM and it was covered with aluminum foil. Both experiments 
were done in duplicate and the results were averaged. 
3.6. aPDT resistance study 
In order to assess the possible development of resistance in bacterial cells after photosensitized 
inactivation, cultures of V. fischeri and E. coli grown overnight were centrifugated at 10,000 g for  
15 minutes to remove dead cells and residues of culture medium, and the cells thus obtained were 
resuspended in PBS (supplemented with 3% of NaCl in the case of V. fischeri). Bacterial suspensions 
(10
7 CFU mL
-1) were equally distributed in 600 mL sterilized and acid-washed beakers and the 
suitable volume of Tri-Py
+-Me-PF solution was added to achieve a final concentration of 5.0 µM (total 
volume was 10 mL per beaker). The samples were protected from the light with aluminum foil and 
incubated for 10 min at 25 °C, under stirring (100 rpm), to promote the porphyrin binding to bacterial 
cells. Afterwards, the mixtures were exposed to white light with a fluence rate of 40 W m
-2 (under 
stirring at 25–28 °C) for 25 minutes. In that way, ca. 1 log unit of surviving bacteria is achieved. At the 
end of each treatment, an aliquot of both samples was plated on TSA and the plates were incubated for 
48 hours at 25 °C in the case of V. fischeri and overnight at 25 °C for E. coli. Three surviving colonies 
from a plate of each bacterium were collected and each one was centrifugated at 10,000 g  
(15 minutes), resuspended in PBS and inoculated on the suitable liquid medium. Subsequently, the 
bacterial suspensions were incubated in the dark with the PS and exposed to visible light using an 
identical irradiation protocol that was repeated for ten times for each bacterium. Before each assay, the 
optical densities (O.D.) of cultures of V. fischeri and E. coli were controlled and monitored to O.D. of 
0.5 and 1.3 (660 nm), approximately. The PI efficiency was expressed as log N0/N, where N0 and N 
represent the bioluminescence signal before and after the irradiation, respectively [42]. 
4. Conclusions 
This study shows that the promising photosensitizer Tri-Py
+-Me-PF is able to destroy efficiently 
Gram-negative bacteria, after the photodynamic treatment, without the recovery of bacterial viability. 
It was also confirmed that the bacteria photosensitized by this photosensitizer do not develop 
resistance mechanisms against the photodynamic process. 
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